Co-Diagnostics

Co-Diagnostics EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Co-Diagnostics (CODX) as of Nov 20, 2026 is 0.16. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 0.57 — a change of -71.40% (lower).

EV/EBITDA

0.16

YoY

-71.40%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Co-Diagnostics is 2025 0.16 . EV/EBITDA (Enterprise Value to EBITDA) of Co-Diagnostics was 2024 0.57 . It decreases by -71.40% lower compared to the previous year.

The Co-Diagnostics EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-1.07 USD
Jan 1, 2019
-0.77 USD
Jan 1, 2020
-1.00 USD
Jan 1, 2021
-1.69 USD
Jan 1, 2022
2.93 USD
Jan 1, 2023
1.21 USD
Jan 1, 2024
0.57 USD
Jan 1, 2025
0.16 USD
The Co-Diagnostics EV/EBITDA history
YEAREV/EBITDAYoY
0.16-71.40%
0.57-52.76%
1.21-58.89%
2.93-273.93%
-1.69+68.89%
-1.00+28.98%
-0.77-27.64%
-1.07+249.86%
-0.31-93.66%
-4.82+42.39%
-3.39-35.00%
-5.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

EV/EBITDA (Enterprise Value to EBITDA) of Co-Diagnostics is 0.16 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Co-Diagnostics changed from 0.57 to 0.16, representing a -71.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Co-Diagnostics

All Key Metrics — Co-Diagnostics